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856 | Food Funct., 2013, 4, 856–870Review of existing experimental approaches for the
clinical evaluation of the beneﬁts of plant food
supplements on cardiovascular function
Paolo Meoni,*a Patrizia Restanib and Dalu T. Mancamabc
We conducted a survey of the National Centre for Biotechnology Information (NCBI) PubMed database to
identify methods most commonly used for the evaluation of the eﬀect of plant food supplements on the
cardiovascular system and their relevance to the regulatory status of these products. Particularly, our search
strategy was aimed at the selection of studies concerning the clinical evaluation of the beneﬁcial eﬀects of
the most commonly studied plant food supplements acting on the cardiovascular system. Following the
screening of 3839 papers for inclusion criteria, 48 published reports were retained for this review. Most
studies included in this review used a double blind controlled design, and evaluated the eﬀect of plant
food supplements on individuals aﬀected by a disease of the cardiovascular system. The majority of the
studies were found to be of low methodological quality on the Jadad scale, mainly because of
inadequate reporting of adverse events and of patient withdrawals. In comparison, measures used for
the evaluation of beneﬁts included mostly cardiovascular risk factors as recommended in international
guidelines and in accordance with principles laid down for the evaluation of health claims in food. The
risk factors most frequently evaluated belonged to the category of “lipid function and levels”, “heart
function” and “blood pressure”. For the absolute majority of the studies, the study period did not
exceed one month. This review highlights critical factors to be considered in the design of studies
evaluating the health eﬀects of plant food supplements on the cardiovascular system. Between others,
the inclusion of healthy individuals, better reporting and description of the characteristics of the
product used could improve the quality and relevance of these studies.Introduction
The cardiovascular system is composed of the heart and the
network of arteries, veins, and capillaries that transport blood
throughout the body, thus delivering oxygen and nutrients
necessary to the proper functioning of the organism. World-
wide, cardiovascular disease is estimated to be the leading
cause of death and loss of disability-adjusted life years.
Cardiovascular diseases are responsible for the largest propor-
tion of deaths due to non-communicable diseases, only fol-
lowed by cancers and chronic respiratory diseases.1
Multivariable assessment has been advocated to estimate
absolute cardiovascular disease risk and to guide treatment
of risk factors eﬀectively reducing the incidence of these
diseases.2,3 Several studies have looked at the correlation ofe H. Bourguiba, 2070 La Marsa, Tunisia.
el: +216 25 57 71 67
Universita di Milano, Via Balzaretti 9,
i@unimi.it; Fax: +39 0250318284; Tel:
1, South Africa. E-mail: dmancama@csir.
1 4282diﬀerent factors with the risk of cardiovascular disease in
diverse populations, and abnormal lipids, smoking, hyperten-
sion, diabetes, abdominal obesity, psychosocial factors, inade-
quate consumption of fruits and vegetables, high levels of
alcohol intake, and lack of regular physical activity account for
most of the risk of myocardial infarction worldwide in both
sexes and at all ages in all regions.4
Based on several lines of evidence, most guidelines2,3 advo-
cate a reduction of these risk factors as an eﬀective way of
reducing the incidence of cardiovascular disease.
Prevailing dietary recommendations focus on reducing and
eliminating unhealthy food components, such as saturated and
trans fats, sodium, and added sugar. This is an important way to
improve overall diet quality, but there is also increasing interest
in nding potentially benecial ingredients for disease
prevention. In particular, emerging evidence indicates that
certain foods or their components might mitigate disease risk
factors and promote general health and well-being.5
Partly because of this close and widely disseminated asso-
ciation between the diet and risk of cardiovascular disease, and
partly because of the beliefs concerning the safety and eﬃcacy
of plants in maintaining health, many people have turned toThis journal is ª The Royal Society of Chemistry 2013
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View Article OnlinePlant Food Supplements (PFS) for conditions associated with
the cardiovascular system.
Of the 10 top selling herbal dietary supplements in the food,
drug and mass market channel in the United States for 2011,6
ve are oen consumed for their purported activity on the
cardiovascular system.7
Regardless of the widespread use of herbal or plant food
supplements, eﬃcacy and safety studies of their activity in
human subjects are limited and oen methodologically poor8
and the selection of the methodology best suited to assess their
activity is of the utmost importance both in scientic and
regulatory terms.
The objective of this review was to conduct a survey of
studies conducted on the most commonly used PFS associated
with the health of the cardiovascular system in order to assess
the quality of methods and their relevance to the specic
regulatory status of PFS.
Food supplements are dened by the Directive 2002/46/EC9
of the European Parliament and of the Council as “the food-
stuﬀs for which the purpose is to supplement the normal diet
and that are concentrated sources of nutrients or other
substances with a nutritional or physiological eﬀect, alone or in
combination, marketed in dose form, namely forms such as
capsules, pastilles, tablets, pills and other similar forms,
sachets of powder, ampoules of liquids, drop dispensing
bottles, and other similar forms of liquids and powders
designed to be taken in measured small unit quantities”. PFS
are also dened in this directive as a type of food supplement in
which botanical preparations are the main ingredients.9
As it can be seen from these denitions and similar deni-
tions applicable to non-European markets,10 from a regulatory
perspective PFS are assimilated to foodstuﬀ, and the benet
claims allowed in the commercialisation of these products
should exclude medical claims such as the prevention, diag-
nosis and treatment of a recognised pathological state.
This situation clearly requires the careful denition of the
population assessed in clinical trials of PFS as well as the
biochemical, pharmacological and clinical endpoints and
methods to be used in the clinical evaluation of the benets
related to the use of PFS. The evaluation of these aspects within
clinical studies of the most commonly researched plants with
activity on the cardiovascular system will be the primary
objective of this review.Research design and methods
Search strategy
A non-systematic review was conducted of the published studies
assessing benets to the cardiovascular system related to the
use of PFS by searching the NCBI PubMed database for studies
published between January 1990 and July 2011.
The search used a combination of terms related to the name
of plants contained in the EuroFIR EBasis database (Bioactive
Substances in Food Information System) and the cardiovascular
function. Use of the EBasis database was motivated by its
inclusion of data from the peer-reviewed literature representing
over 300 major European plant foods. General terms related toThis journal is ª The Royal Society of Chemistry 2013the cardiovascular system were combined with keywords related
to pathologies included in the 10th edition of the International
Classication of Disease11 and comprised: heart OR cardiovas-
cular OR hypertension OR hypertensive OR hypotension OR
ischemic OR heart disease OR cerebrovascular OR conduction
OR arrhythmias OR infarction OR cerebrovascular OR athero-
sclerosis OR thrombosis OR phlebitis OR haemorrhoids OR
varicose.
Inclusion criteria
To be included in this review, studies had to (i) primarily
concern the clinical evaluation of PFS, (ii) include the evalua-
tion of benecial eﬀects (benets) of PFS on the cardiovascular
system, (iii) be published in the English language, (iv) be
representative of the most commonly studied plant ingredients
within PFS.
To assess the eligibility of the studies to these inclusion
criteria, the following denitions were used:
Benet – this denition was developed by consortium part-
ners within PlantLIBRA (EC project number 245199): “the
attainment of specic physiological objectives, such as reduc-
tion of risk factors for chronic diseases and the maintenance of
the human homeostasis, which is the body's capability to
physiologically regulate well-being and ensure stability and
balance in response to changes in the external environment”.
Plant food supplements – the denition of PFS was aligned
with the EC Directive 2002/46 of the European Parliament and
of the Council of 10 June 2002 (ref. 9) on the approximation of
the laws of the Member States relating to food supplements:
“the foodstuﬀs (in which botanical preparations are the main
ingredients) for which the purpose is to supplement the normal
diet and that are concentrated sources of nutrients or other
substances with a nutritional or physiological eﬀect, alone or in
combination, marketed in dose form, namely forms such as
capsules, pastilles, tablets, pills and other similar forms,
sachets of powder, ampoules of liquids, drop dispensing
bottles, and other similar forms of liquids and powders
designed to be taken in measured small unit quantities”.
Clinical evaluations: clinical trials based on all study designs
including case-control studies, nested case-control studies, cross-
sectional studies, parallel- or cross-over trials; trials comprising
subjects of all conditions, age, gender, and racial groups.
Exclusion criteria
Studies not in the English language.
Data extraction and quality assessment
Studies meeting the criteria for selection were extracted into a
spread-sheet that captured the following data: trial type
(blinding, randomisation, design, duration), population size,
methodological quality according to the work of Jadad,12
inclusion and exclusion criteria (age, diagnosis, exclusion
criteria), treatment (product name, manufacturer, drug
substance, country of origin, dosage form, strength), exposure
(dosage), outcome measures (outcome, level of signicance,
technology used), adverse events.Food Funct., 2013, 4, 856–870 | 857
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View Article OnlineResults
Literature search and study characteristics
The literature search methodology and results are summarised
in Table 1. The initial interrogation of the NCBI database with
cardiovascular function terms crossed with plant names and
synonyms from the EuroFIR database resulted in the identi-
cation of 3839 studies of potential relevance. The titles and
abstracts of these studies were then screened to identify reports
dealing with clinical studies and resulted in a reduced list of
238 reports.
To reduce the number of studies and concentrate the review
on PFS containing plant ingredients from most extensively
researched plants included in food supplements, we used two
diﬀerent lters: rstly plants mainly used as foods and in a food
form (rice, maize, orange, peanut, grapefruit, rye, beetroot,
walnut, potato) were excluded resulting in a consolidated list of
159 entries.
Secondly, based on the number of studies identied per
plant species, only plants associated with at least three reports
of clinical studies were considered as the most extensively
researched sources of plant food supplements (Table 2) result-
ing in the identication of 106 clinical reports considered to be
the main focus of this review.
The plants thus identied were: Lycopersicum esculentum or
Solanum lycopersicum (tomato), Ruscus aculeatus (Butcher's
broom), Centella asiatica (centella), Camellia sinensis (tea),Table 1 Summary of the literature search methodology and results
Number of
papers
Potential studies identied in database search 3839
Studies involving human trials 238
Studies on most extensively researched plants 106
Number of full papers obtained and reviewed 100
Number of papers meeting inclusion criteria 48
Table 2 Most extensively researched plants based on the present review of
clinical studies
Scientic name Common name
Prioritisation of studies
based on top
non-food plants
Lycopersicum esculentum Tomato 30
Ruscus aculeatus Butcher's Broom 11
Centella asiatica Centella 9
Camellia sinensis Tea 9
Vaccinium macrocarpon Cranberry 8
Allium sativum Garlic 8
Hibiscus sabdariﬀa Roselle 7
Cynara cardunculus Artichoke 6
Panax ginseng Ginseng 6
Glycine max Soy 4
Citrus aurantum Bitter orange 4
Olea europea Olive tree 4
858 | Food Funct., 2013, 4, 856–870Vaccinium macrocarpon (cranberry), Allium sativum (garlic),
Hibiscus sabdariﬀa (roselle), Cynara cardunculus or Cynara sco-
lymus (artichoke), Panax ginseng (ginseng), Glycine max or Soy
lecithins (soy), Citrus aurantium (bitter orange), Olea europea
(olive). Most of these plants were ambivalent, with a signicant
use as food, but also with a consolidated use as ingredients in
PFS (tomato, tea, cranberry, garlic, artichoke, soy, olive) in
forms compatible with this class of products.
The full article of each study was subsequently retrieved for
detailed examination prior to selecting the nal subset of
studies for extraction.
Full article reviews were not possible for 6 articles as these
were not available from the source, while a further 52 did not
meet all inclusion criteria.
The most common reasons for failure to meet inclusion
criteria were related to the denition of plant food supplements,
mainly due to the lack of processing (so that the plant material
was consumed in the same form as a food, like in many reports
of tomato-based products) or dose form (as an example, none of
the reports identied for cranberry could be included as
they were performed on cranberry juice, also commonly used as
a food).
Most of the plant food supplements included in this review
were administered orally in capsule form (43 out of the 48
studies) followed by liquid forms.
A total of 48 articles were eventually included in the nal
data extraction set (Table 3); of these 22 were based on double-
blind controlled trials, 21 were based on open trials; and the
remainder 5 studies were single blind trials (see Fig. 1).
The majority of the studies used a randomisation method to
assign participants to the diﬀerent treatment groups, with 19/21
double blind studies, 4/5 single blind and 6/21 open studies
using randomisation (Fig. 2).
Most studies (26/48) looked at the eﬀect of PFS on individ-
uals aﬀected by a disease recognized in ICD-10 or otherwise
identied by the authors, thus referring to the intervention with
the PFS as a treatment for patients included in the study. When
studies were ranked according to the population considered,
the proportion of double blind vs. open studies seemed higher
in the healthy population (Fig. 3).Study population and duration
As summarised in Table 3, the inclusion criteria for the study
population and the clinical outcomes being assessed varied
widely across studies; thesemainly included healthy individuals
(26 out of the 48 studies) but a signicant number of studies
were performed on pre-pathological to pathological cardiovas-
cular conditions ranging from the presence of risk factors
(dislypidemias) to minor pathologies (such as minor to
moderate supercial venous disease), to chronic diseases
(hypertension).
Interestingly, some studies concentrated on borderline
conditions (borderline hypertensive, slightly elevated levels of
cholesterol) which for the purpose of this review and the clas-
sication used in Table 3 were categorized as dealing with
healthy populations.This journal is ª The Royal Society of Chemistry 2013
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View Article Online
Fig. 1 Repartition of studies according to the study design and the presence of a
comparator.
Fig. 3 Repartition of studies according to blinding protocols and the status of
the selected population.
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View Article OnlineThe duration of treatment periods included in the studies on
average extended to 82 days, with studies on healthy volun-
teers presenting (on average) a shorter treatment duration
(34 days) than studies looking at the eﬀect of PFS in diseased
populations (122 days). This diﬀerence was mainly driven
by three studies looking at the eﬀect of PFS in diseased pop-
ulations for longer than 4 months,35,40,46 and excluding these
studies the average duration of studies on diseased pop-
ulations fell to 53 days.
Average group size across all studies was of 72 individuals,
and within this dimension a diﬀerence between studies looking
at healthy volunteers and diseased population could again be
observed (24 versus 112 respectively). Similarly to the analysis of
study duration, this diﬀerence was mainly driven by three
studies35,51,58 in the diseased population group. Excluding these
outliers from the analysis, the average group size between the
two categories was more comparable (24 and 31 for the healthy
and diseased populations respectively).Fig. 2 Repartition of studies according to the randomisation protocol and
study design.
This journal is ª The Royal Society of Chemistry 2013Quality of study reporting
The quality of study reporting was assessed with the Jadad
scale,12 a commonly used instrument to assess the quality of
clinical studies. The quality evaluation using this method relies
on the rater's evaluation of the report information related to
randomization (up to two points), study blinding (up to two
points) and description of withdrawals and drop-outs (up to one
point). Studies with the highest quality would get a maximum of
5 points, whilemethodologically poor studieswould get 0 points.
For the purpose of this review, a score of 0–2 would be
considered as a low quality study while scores of 3–5 be asso-
ciated with high quality.
The overall quality of study design, as assessed by the
methodological quality score in the data extraction form (as
dened in 12) was found to vary widely across studies. The
majority were assessed to be of moderate to low quality (average
across all studies 1.875) with a slightly higher proportion ofFig. 4 Repartition of studies according to quality score and the status of the
selected population.
Food Funct., 2013, 4, 856–870 | 863
Table 4 Summary of methods used to assess beneﬁts of plant food supplements
on the cardiovascular system
Category of methods Methods (references)
Clinical evaluation Body weight30,50,53,54
BMI50,54
Arm, waist and hip circumference50
Body composition20,50
Food intake50
Disease symptoms19,30,48,50–53
Eﬀectiveness scale51,59,60
Safety scale59,60
Tolerance scale60
18,58
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View Article Onlinehigh quality reports (Jadad quality score >2) within studies of
healthy populations (Fig. 4).
Studies looking at the eﬀects of plant food supplements in
healthy individuals had a higher proportion of high-quality
studies (41% vs. 31% in studies on diseased populations) and a
higher proportion of double-blind, randomised and controlled
studies (59% vs. 34% in studies on diseased populations) (Fig. 4
and Table 3).
Overall, the main reasons for low scores on the Jadad
scale were poor reporting of adverse events and withdrawals,
followed by incomplete description of randomisation methods
and blinding.Quality of life scale
Blood chemistry19,30,48,50–53
Venous and arterial
structure and function
Beta-n-acyl glucosaminadase44
Arylsulfatase44
Uronic acid44
Endothelial progenitor cells14
VCAM-I47
ICAM-I47
E-selectin47
Macrocirculatory evaluation43,57,59
Microcirculatory evaluation41,56
Maximum venous outow45
Flow-mediated brachial artery
vasodilation16,22,47
Flow-mediated endothelium-dependent
vasodilation14
Portal vein cross section34
Femoral vein cross section34
Venous distension and tone59
Vascular resistance34
Capillary ltration rate43,45,46
Skin blood ow42
Carotid plaque evaluation35,40
Arterial stiﬀness13,31
Ankle and/or leg circumference45,46,57,58,60
Ankle oedema coin test45
Vacuum suction chamber42
Heart function and
blood pressure
ECG32
Heart rate17,30,32
Diastolic and systolic blood
pressure13,15,17,22,25,30–32,39,51–55Study outcomes
Most of the studies included in this review looked at a wide
number of outcomes, oen including a combination of
biochemical, functional and clinical measurements. Outcome
measures and treatment-related adverse events are summarised
in Table 3. The majority of the studies (43 out of 48, see Table 3)
reported a signicant eﬀect of the PFS on at least one of the
benet measures used to assess its biological activity (partial
statistical signicance as indicated in Table 3), and only a
minority did not observe a signicant eﬀect on at least one
outcome measure. None of the studies mentioned the inclusion
of statistical correction factors for multiple comparisons.
Interestingly, most of the ve studies13,25,27,39,48 not reporting any
signicant eﬀect belonged to the lower tier in terms of pop-
ulation size, thus suggesting that this could be a critical factor
in the observed lack of eﬃcacy.
A signicant proportion of the studies (21 out of 48) did not
report on the occurrence, nature or prevalence of adverse events
observed during or aer PFS exposure. Of the studies reporting
on adverse events, the majority (19 out of 27) did not record any
occurrence, and generally only mild adverse events were
observed in conjunction with the use of PFS included in these
studies (Table 3).Venous pressure44,59
Cardiac output34
Le ventricular diastolic volume34
ACE activity51
Treadmill (multiple parameters)36
Coagulation parameters Platelet aggregation23,24,29
Platelet ATP release29
Prothrombin time23
Thrombin clotting time23
Fibrinogen37
Fibrinolytic activity37
Ex vivo thromboxane formation37
Lipidemia, lipid function
and risk factors
TC13,15,16,18–22,26,27,30,33,37,38,47–50,52,53,55
HDL13,16,18–20,22,26,27,30,33,37,38,47–50,52,53,55
LDL13,15,16,18,22,26,30,33,38,47–50,52,53,55
VLDL48,49,52
TG13,16,18–20,22,26,27,33,37,38,47,48,52,53,55
Free fatty acids20
Apolipoprotein A120,53
Apolipoprotein B38
Apolipoprotein B10053Methods for assessing the cardiovascular benets of PFS
A wide range of methods were identied that are used for
assessing the benets of PFS on cardiovascular function, and
these could be categorised into six categories: clinical evaluation;
venous and arterial structure and function; heart function and
blood pressure; coagulation parameters; lipidemia lipid function
and risk factors; inammatory status andoxidative stress. A list of
the methods included in each category is reported in Table 4.
The class presenting the highest diversity and number of
methods was the “venous and arterial structure and function”
(24 methods), followed by “inammatory status and oxidative
stress” (18 methods) and “lipidemia, lipid function and risk
factors”(13 methods). However, many methods identied in
this survey were oen used only in individual studies (for
example the ankle coin test in ref. 45 and the vacuum suction
chamber for the measure of oedema in ref. 42) (Tables 3 and 4),
so that the number of studies in each category cannot be taken
as representative of the popularity of the method.864 | Food Funct., 2013, 4, 856–870 This journal is ª The Royal Society of Chemistry 2013
Table 4 (Contd. )
Category of methods Methods (references)
Serum amyloid alpha15
Plasma homocysteine53
Choline, betaine22
Urinary 8-isoprostaglandin-F2-alpha28
Inammatory status and
oxidative stress
IFN gamma28
TNF alpha28
DNA damage28
Erythrocyte sedimentation rate14
C-reactive protein14
LDL-conjugated diene26
LDL malondialdehyde26
Serum malondialdehyde15,33
Anti-oxidised LDL IgG16
Anti-oxidised LDL IgM16
Total antioxidant activity19,27
Superoxide dismutase19,33
Thiobarbituric acid reactive
substances16,19,53
Glutathione peroxidase19,53
Erythrocyte glutathione19
Plasma thiol levels53
Plasma vitamine E53
Nitrite/nitrate54
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View Article OnlineWhen the frequency of utilisation of the identied methods
was taken into account, themethodsmost oen used were those
for “lipidemia, lipid functionandrisk factors” (averageutilisation
of 6.5), “heart function and blood pressure” (average utilisation
3.0) and “clinical evaluation” (average utilisation 2.9, see details
in Table 5). As expected, the class with the highest number of
methods (venous andarterial structure and function)wasalso the
one presenting one of the lowest average utilisation per method.
Within the categories, a large variability in utilisation was
observed between diﬀerent methods. The methods most
commonly used were lipidemic measures such as TC, HDL, LDL
and TG as well as the measure of systolic and diastolic blood
pressure which were all used in more than 30% of the identied
studies.
Of particular note was the relatively scarce use of alternative
indicators of risk factors (lipoproteins, homocystein, urinaryTable 5 Descriptive statistics on method utilisation across the studies included in
Class of methods
Number of
methods
Clinical evaluation 11
Venous and arterial structure and
function
24
Heart function and blood pressure 8
Coagulation parameters 7
Lipidemia, lipid function and risk
factors
13
Inammatory status and Oxidative
stress
18
a Average utilisation per method was dened as the average number of stu
PFS on the specic class.
This journal is ª The Royal Society of Chemistry 2013isoprostaglandin-F2-alpha) and the exclusion of other estab-
lished biomarkers that may be of particular interest in the
context of plant food supplements.Discussion
This review was motivated by the perceived poor methodolog-
ical quality of studies used to assess the eﬃcacy of PFS in
cardiovascular disease in light of the absence of clear guidelines
concerning their evaluation. Through the review of published
studies in this eld, we aimed at the determination of the main
determinants of these studies and to the assessment of their
relevance to the specic regulatory status of PFS.
The analysis of studies included in this review conrmed a
wide heterogeneity in the study design and overall quality of
evaluations of PFS benets. While outcomes used for assessing
the cardiovascular benets of PFS seemed generally to be
adequate to characterise their activity on the cardiovascular
system, two areas of concern couldbe identied, namely the study
design (particularly the population included in the study and the
durationof treatment) and the characteristics of theproductused.
A number of review papers have already dealt with the toxi-
cological evaluation of plant food supplements currently used
in the market61–65 and some guidance documents have been
made available by diﬀerent regulatory bodies,65–67 the matter
related to the evaluation of the benets associated with the use
of plant food supplements remains less explored. EU regula-
tions on nutrition and health claims published in 200668 set out
the general principle for all health claims to have pre-marketing
approval by EFSA, but the regulation did not lay down detailed
criteria or requirements for the data supporting a specic
health claim (see ref. 69 for a wide overview of the subject).
In the eld of standard foods, the PASSCLAIM project70 set
out criteria for the scientic substantiation of product-specic
claims, and the same project recommended an evidence-based
assessment of existing studies consisting of the identication,
evaluation, and interpretation of individual studies leading to a
case-by-case assessment of the validity of the product's health
claim. Both the PASSCLAIM project70 and the Consensus
Document of the Scientic Concepts of Functional Foods in
Europe initiative (FUFOSE) indicated that the health promotingthis review
Methods utilisation
(number of occurrences in
papers included in this review)
Average
utilisation
per methoda
32 2.9
37 1.5
24 3.0
9 1.3
84 6.5
23 1.3
dies using the particular method within the studies looking at eﬀects of
Food Funct., 2013, 4, 856–870 | 865
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View Article Onlineeﬀects specic to foods or food components should be mainly
exerted through disease risk reduction, thus suggesting that the
health-maintaining or promoting eﬀects of PFS could be ideally
assessed on disease-progression biomarkers and risk factors
(for a review see ref. 69).
Within this context, cardiovascular disease represents an
extremely interesting case for the evaluation ofmethods assessing
PFS' benets as the transition between health and disease and the
key markers of this progression have been thoroughly charac-
terised andplacedwithina continuum.The cardiovascular disease
continuum was rst described as a chain of events, initiated by a
myriad of related and unrelated risk factors and progressing
through numerous physiological pathways and processes to the
development of end-stage heart disease.71 While this concept was
initially formulated for coronary artery disease, it has now been
expanded to diﬀerent areas of cardiovascular disease sharing
similarpathophysiological processes.72,73Withinall thesediseases,
a number of biomarkers and risk factors capable of determining
the relative position of specic individuals along this continuum
from health to disease have been described.3,4,74
Methods more oen used in studies included in this review
seemed to be appropriate for the evaluation of their impact on
cardiovascular disease. The three categories of methods with
the highest average utilisation per method were represented by
the “lipidemia, lipid function and risk factors”, “heart function
and blood pressure” and “general clinical evaluation”
(including symptoms but also general body parameters and
quality of life scales).
Most guidelines2,3 recommend cardiovascular risk evalua-
tion in healthy individuals including factors included in these
high average utilisation classes and including the measure of
body parameters (weight, BMI), cholesterol levels (TC, HDL,
LDL) and blood pressure.
Lipidemia (including total cholesterol, HDL and LDL
cholesterol) and systolic and diastolic blood pressure were the
most frequent methods assessing the eﬀect of plant food
supplements, and are the key factors in the evaluation of the
risk of cardiovascular disease. As these parameters are
commonly evaluated in clinical practice, clinical and laboratory
methods that are both aﬀordable and reliable are widely avail-
able and should be routinely used in the evaluation of PFS
activity on the cardiovascular system.
In comparison, biomarkers associated with an intermediate
level of evidence in guidelines from the American Societies
(C-reactive protein, hemoglobin A1C, urinary albumin excretion,
lipoprotein-associated phospholipase A2),3 or other novel
biomarkers of late (creatine kinase and creatine kinase-MB,
myoglobin, lipoprotein A, brain natriuretic peptide, troponins I
andT,osteopontin) and early stage (asymmetricdimethylarginine,
myeloperoxidase, F2 isoprostanes between others) diagnostic
potential74 were hardly included in the studies reviewed here.
In conclusion, while biomarkers commonly recommended
for cardiovascular risk evaluation were included in the majority
of the studies, inclusion of wider panels of biomarkers and risk
factors could be particularly desirable and useful in proling
and characterising the health eﬀects of plants commonly used
in PFS used to promote cardiovascular function.866 | Food Funct., 2013, 4, 856–870Access to a larger panel of biomarkers could both provide
more resolution for ngerprinting and diﬀerentiating the
eﬀects of diﬀerent PFS, and more information on the time-
course of the PFS eﬀect at diﬀerent stages of the continuum.
Critical features aﬀecting the overall quality of studies sup-
porting product-specic claims were discussed within the
PASSCLAIM project. The most important features were identi-
ed as the appropriateness and validity of the study method-
ology used, the completeness and description of analytical
measures and the adequacy of the study population, between
others.70 These important features also appear critical from the
analysis of the studies included in this review. In particular,
the study population and study methodology (particularly the
design and duration of the studies) did not always seem
adequate for the evaluation of PFS benets.
Over half of the studies identied in this review dealt with
patient populations diagnosed with pathological conditions
ranging from mild arterial or venous hypertension, to varicose
veins, to more severe and possibly life threatening conditions
such as severe hypertension or advanced atherosclerotic plaques
in thepresence of other risk factors.While this situation could be
partly explained by the inclusion of ambivalent plants (i.e. plants
used in plant food supplements and medicinal products in
diﬀerent countries), it certainly highlights some confusion in the
selection of the population to be assessed for the health main-
taining or promoting activity of plant food supplements, and
calls for the inclusion of individuals at an earlier stage in the
cardiovascular continuum. The study of diseased populations
also added specic constraints that diminished the quality of
studies: double blind protocols weremore diﬃcult to implement
in this population, and the overall quality score was lower. The
low quality scores of the studies on the Jadad scale were associ-
ated with important shortcomings in the reporting of adverse
events, drop-outs and withdrawals, blinding procedures. While
this diﬀerence can be partly explained on ethical grounds
(patient's lack of improvement can be better detected and more
promptly corrected in single blind or open studies), it certainly
further supports the use of healthy volunteers in the assessment
of the health promoting eﬀects of plant food supplements.
The duration of the studies also diﬀered between healthy
and diseased populations, and the comprehension of this
diﬀerence should be key to the formulation of recommenda-
tions for further studies. The longer duration of the studies in
diseased populations corresponds to the inclusion of disease-
specic outcomes whose regression to normal values is slower
than any eﬀect on risk factors. Parameters of venous and arte-
rial function in circulatory disease, blood pressure and lip-
idemia in hypertensive and hyperlipidemic patients or plaques
regression in atherosclerotic patients for example required long
intervention times than studies looking at risk factors in
healthy volunteers. As an example, the two longest studies
included in this review35,40 both looked at the most severe
condition included in this study set: plaques regression and
characteristics in patients with advanced and/or high risk
atherosclerotic plaques.
Therefore, considering the regulatory status of PFS and their
suggested activity in the reduction of risk factors,69,70 durationsThis journal is ª The Royal Society of Chemistry 2013
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View Article Onlineof two to threeweeks should generally be considered suﬃcient to
highlight a physiological eﬀect andbedeemed suﬃcient to study
PFS benets on biomarkers related to the cardiovascular system.
A nal consideration concerns the description of the mate-
rial used in the studies. As mentioned previously, the formu-
lation as well as the process and the chemical characterisation
of the raw and nal material is key to determine the identity and
quality of the PFS, and the belonging of a certain product to the
category of Food Supplement, Food or Medicine.
Many studies were performed on plant material that was
poorly characterised or whose formulation was not suﬃciently
described and generally did not correspond to the commercial
formulations available in shops. Very few studies included in
this review for example provided a commercial name or the
exact composition of the product tested.
More stringent criteria should be applied to the character-
isation of the PFS ingredients (standardisation, chemical
proling, quantitative content of biomarkermolecules) aswell as
on the pharmaceutical form used for the study to improve the
relevance of study results to the actual use of the product on
the market.
In conclusion, while the results of this review cannot be fully
representative of all the studies conducted on cardiovascular
eﬀects of PFS, they highlight some areas of major concern in the
design of studies for the assessment of PFS benets in cardio-
vascular disease: rstly, studies should be conducted on healthy
populations, using a wider panel of measures and for durations
suﬃcient to unequivocally assess the eﬀect on risk factors and
associated clinical outcomes; secondly, study reports should
report more precisely protocol details (randomisation, blinding,
statistical analysis) as well as study-related events such as
adverse events andwithdrawals. Finally, interventions should be
better characterised from the product perspective by adequately
describing the composition and formulation of the PFS.
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